Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
29 Diciembre 2023 - 8:40AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2023
Commission File No. 001-35193
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
x Form 40-F
o
Grifols, S.A.
TABLE OF CONTENTS
| Grifols, S.A.
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA
Tel. [34] 935 710 500
Fax [34] 935 710 267
www.grifols.com
|
Pursuant to the provisions of article 226 of the
Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. (“Grifols” or the “Company”)
hereby informs about the following
INSIDE INFORMATION
As a continuation of the Inside Information communication
published on June 14, 2023, regarding Grifols’ interest in Shanghai RAAS Blood Products Co., Ltd. (“SRAAS”),
Grifols informs of the following:
Grifols has reached a Strategic Alliance and Share
Purchase Agreement with Haier Group Corporation (“Haier”) for the sale of approximately a 20% equity stake in SRAAS in
exchange for RMB 12.5 billion (approximately US$ 1.8 billion), while retaining a stake in SRAAS of 6.58%. Haier may designate its affiliates
to complete the transaction. The completion of the transaction is subject to customary regulatory approvals and buyer’s confirmatory due
diligence.
Haier is a leading global provider of better life
and digital transformation solutions and has a growing presence in the healthcare industry. Its subsidiary Haier Smart Home is named among
the Fortune’s Global 500 and World’s Most Admired Companies.
Shares are being sold at a price of RMB 9.405 per
share, which represents a premium of 14.96% to SRAAS’ volume weighted average price over 20 prior trading days, which is RMB 8.181.
The current commercial strategic collaboration
arrangements between Grifols and SRAAS remain in place. The parties have agreed that Grifols will keep one board member at SRAAS’ Board
of Directors.
Grifols and SRAAS will amend the existing Exclusive
Distribution Agreement of human serum Albumin to the Chinese market entered into with SRAAS to extend its current term for an initial
period of 10 years (until 2034), having SRAAS the option to extend for an additional 10 year period, with guaranteed minimum supply volumes
for 2024-2028 period.
Grifols and the buyer commit to not transferring
any portion of their shares in SRAAS within a period of 3 years following the completion of the transaction.
The proceeds from this transaction will be used to reduce debt.
With this transaction, Grifols is able to keep
its presence in China, maintains its commercial agreements with SRAAS in place, and at the same time, complies with its commitment to
deleverage.
In Barcelona, on 29 December 2023
Nuria Martín Barnés
Secretary to the Board of Directors
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A. |
|
|
|
|
|
|
|
By: |
/s/ David I. Bell |
|
|
Name: |
David I. Bell |
|
|
Title: |
Authorized Signatory |
Date: December 29, 2023
Grifols (NASDAQ:GRFS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Grifols (NASDAQ:GRFS)
Gráfica de Acción Histórica
De May 2023 a May 2024